Background Neutralizing antibodies are approved drugs to treat coronavirus disease-2019
(COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS …

Since the coronavirus disease outbreak in 2019, several antibody therapeutics have been
developed to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge and spread around the world, antibodies and vaccines to confer broad and potent …

Neutralizing antibodies have been proven to be highly effective in treating mild and
moderate COVID-19 patients, but continuous emergence of SARS-CoV-2 variants poses …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …

Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants
of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and …

Many SARS-CoV-2 neutralizing antibodies (nAbs) lose potency against variants of concern.
In this study, we developed 2 strategies to produce mutation-resistant antibodies. First, a …

COVID-19 is the deadliest respiratory virus pandemic since 1918 and the latest of several
coronavirus epidemics and pandemics in recent years. Despite the unprecedented …

Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The
evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced …

The rapid adaptation of SARS‐CoV‐2 within the host species and the increased viral
transmission triggered the evolution of different SARS‐CoV‐2 variants. Though numerous …